- Home
- MRUS vs PTGX Comparison
MRUS vs PTGX Comparison
Compare MRUS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- PTGX
- Stock Information
- Founded
- MRUS 2003
- PTGX 2006
- Country
- MRUS Netherlands
- PTGX United States
- Employees
- MRUS N/A
- PTGX N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- MRUS Health Care
- PTGX Health Care
- Exchange
- MRUS Nasdaq
- PTGX Nasdaq
- Market Cap
- MRUS 4.1B
- PTGX 3.3B
- IPO Year
- MRUS 2016
- PTGX 2016
- Fundamental
- Price
- MRUS $66.82
- PTGX $55.15
- Analyst Decision
- MRUS Strong Buy
- PTGX Strong Buy
- Analyst Count
- MRUS 13
- PTGX 9
- Target Price
- MRUS $88.54
- PTGX $67.11
- AVG Volume (30 Days)
- MRUS 645.9K
- PTGX 790.5K
- Earning Date
- MRUS 08-04-2025
- PTGX 08-05-2025
- Dividend Yield
- MRUS N/A
- PTGX N/A
- EPS Growth
- MRUS N/A
- PTGX N/A
- EPS
- MRUS N/A
- PTGX 0.86
- Revenue
- MRUS $54,732,000.00
- PTGX $207,801,000.00
- Revenue This Year
- MRUS $68.08
- PTGX N/A
- Revenue Next Year
- MRUS $0.09
- PTGX $53.09
- P/E Ratio
- MRUS N/A
- PTGX $63.95
- Revenue Growth
- MRUS 42.77
- PTGX N/A
- 52 Week Low
- MRUS $33.19
- PTGX $32.50
- 52 Week High
- MRUS $67.07
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- MRUS 77.27
- PTGX 56.72
- Support Level
- MRUS $61.51
- PTGX $51.55
- Resistance Level
- MRUS $64.00
- PTGX $57.73
- Average True Range (ATR)
- MRUS 2.32
- PTGX 1.74
- MACD
- MRUS 1.02
- PTGX -0.07
- Stochastic Oscillator
- MRUS 97.35
- PTGX 69.13
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.